**INTRODUCTION**

The genus *Alyssum* contains about 175 species and belongs to the Brassicaceae (previously Cruciferae) family. Its main habitat is in temperate and mountainous regions of Asia, Africa, America, and Europe. 27 *Alyssum* species are distributed in Iran that their seeds are known as “qodume / ku:doʊmee/” and are used for medicinal purposes.\(^1\) Flax-leaf *Alyssum* (*Alyssum linifolium* Steph. ex Willd.) is an annual weedy plant commonly distributed in semi-arid areas of Iran.\(^2\) Traditionally, mucilage of the plant seeds is used for respiratory diseases such as cough and hoarseness.\(^3\) Several bioactive glucosinolates (GSLs),\(^4\) phenolic compounds,\(^5\) and fatty acids\(^6\) have been identified from *Alyssum* species with potential cytotoxic,\(^5\) neuroprotective,\(^7\) anti-parasitic,\(^8\) antioxidant,\(^5\) and antimicrobial\(^6\) activities.

GSLs and their enzymatic hydrolysis products are groups of compounds with sulphur atoms found abundantly in seeds and other parts of Brassicaceae plants. Recently, the promising
chemoprotective, anti-tumor, anti-parasitic, and biopesticide activities of GSL compounds have been reported. The anti-parasitic activities of GSLs and their hydrolysis products (such as isothiocyanates) have previously been demonstrated, including the nematicidal and antipROTOzoal effects. Based on the literature reviews, no study has yet examined the effect of GSLs against Leishmania species. The intracellular parasitic protozoan, Leishmania spp. are mostly distributed in North Africa, Middle East, and Central Asia. The female sandflies that are infected by Leishmania spp. can disseminate the parasites. It causes several forms of diseases in humans such as cutaneous, mucocutaneous, and visceral leishmaniasis. The major clinical manifestations of leishmaniasis include fever, jaundice, dyspnea, and hematologic disorders. Due to the high cytotoxicity and drug resistance to the available medications for treating leishmaniasis, recent investigations have been focused on the new resources such as active ingredients from medicinal plants.

According to anti-parasitic potential of Brassicaceae plants and the widespread distribution of Alyssum linifolium in Iran, we evaluated the anti-leishmanial activity of the GSL fraction from A. linifolium seeds in both promastigote and amastigote stages of Leishmania major parasites. The purification and identification of the major GSL constituents of A. linifolium seeds were performed by chromatographic techniques (ion-exchange and reversed-phase chromatography), electron ionization-mass spectrometry (EI-MS) and nuclear magnetic resonance (NMR) spectroscopy. For further investigation of the volatile constituents in A. linifolium seeds (isothiocyanates and nitriles), the gas chromatography-mass spectrometry (GC-MS) method was performed.

MATERIALS AND METHODS

Experimental instruments

Ultraviolet-visible spectrophotometer: PG Instruments (T80-series, Lutterworth, UK). EI-MS: (Agilent Technologies, Santa Clara, USA). NMR spectroscopy (1H- and 13C-NMR): Bruker Advance III Spectrophometer, (Billerica, MA, USA).

Preparation of glucosinolate fraction and identification of the major glucosinolates

The seeds of A. linifolium were collected and authenticated by Dr. Yousef Ajani from Karaj, Iran (May 2019). The voucher herbarium specimen (105795) was deposited at the Research Institute of Forests and Rangelands, Tehran, Iran. The GSL fraction was prepared according to our previous study. Briefly, the ground seeds were extracted with hot methanol and the resulting extract was loaded onto the DEAE Sephadex A-25 column. The sulfatase (S9626, Sigma) solution was added to the column for the desulfation of GSLs. For further purification, the GSL fraction was loaded onto a vacuum-liquid chromatography (VLC) column packed with C18-reversed phase silica gel and eluted with aqueous CH3CN. The separation of GSLs was achieved using high performance liquid chromatography (HPLC). The data from EI-MS and 1H-13C-NMR spectroscopy were used for the structural analysis.

HPLC analysis

The semi-preparative purification of the desulfo-GSL fraction was performed on Knauer equipment including the WellChrom pump K-1800 and C18 gravity-SB column (250 × 20 mm). Separation of the desulfo-GSLs was carried out using water (A) and acetonitrile (B) programed as follows: 0-1 min, 1% B; 1-25 min, linear gradient up to 22% B; 25-29 min, linear gradient drops down to 1% B; flow rate: 8 mL/min; injection volume: 5 mL; wavelength: 229 nm.

Determination of total glucosinolate content

The quantification was done according to Jezek et al. In this method, GSLs are hydrolyzed by sodium hydroxide to release 1-thioglucose and the latter compound reacts with a potassium ferricyanide solution. The absorbance of the solution was measured at 420 nm using a spectrophotometer. Various concentrations of sinigrin (0-1 mg/mL) were applied for plotting the standard curve.

Volatile fraction preparation

Hydrodistillation was achieved using a Clevenger-type apparatus. A. linifolium seeds were used for the extraction of volatile compounds. Hydrodistillation was achieved for 3 h and the volatiles were trapped by pentane. Anhydrous sodium sulfate was used to dry the volatile fraction. The concentrated fraction was analyzed using GC-MS. An Agilent 6890 gas chromatograph consisting of a BPX-5 MS capillary column (30 m × 0.25 mm) was employed under the following conditions: temperature gradient: 50°C; for 5 min, 240°C at 3°C/min, 300°C at 15°C/min; carrier gas: helium, flow rate: 0.5 mL/min; MS mode: EI; detector voltage: 70 eV; mass range: 40 to 500 m/z.

Parasite culture

The promastigotes of L. major (MRHO/IR/75/ER) were cultured in NNN medium, then sub-cultured in RPMI-1640 medium (Gibco) supplemented with 10% heat inactivated fetal bovine serum, 100 μg streptomycin, and 100 IU penicillin (Gibco, Scotland, UK).

Anti-leishmanial activity

In vitro anti-promastigote activity assay

The evaluation was carried out for 72 hours incubation in 96 well plates. The 2-fold serial dilutions of the GSL fraction were prepared at the concentrations of 15-125 μg/100 μL of RPMI-1640 medium. As positive controls, amphotericin B and glucantime were diluted serially in two-fold steps at concentrations of 0.98-7.8 and 140-18.700 μg per 100 μL of RPMI, respectively. Next, 100 μL of each concentration of GSL fraction or standard drugs was added to the wells in triplicate. Finally, 100 μL of RPMI-1640 medium supplemented with 1 × 10⁵ promastigotes, was added to wells (final volume of 200 μL). All above concentrations were calculated per mL for IC₅₀. The number of 3 untreated wells containing the parasite was used as the negative control. After incubation (72 h), the amount of 20 μL of each well was mixed with an equal volume of 2% formaldehyde solution in phosphate-buffered saline (PBS). The promastigotes/mL were calculated in a hemocytometer under a light microscope (400× magnification) by mixing 20 μL.
of each well content with an equal volume of 2% formaldehyde solution in PBS, pH 7.2. The following formula was used for measuring the death rate (DR):

\[
DR(\%) = \left(\frac{NC - DT}{NC}\right) \times 100
\]

Here, NC and DT denote the promastigotes number in negative control and treated wells, respectively.

**In vitro anti-amastigote assay**

The macrophage cell line (murine J774A.1) from the Pasteur Institute (Tehran, Iran) was cultured in RPMI medium and added to a 96 well plate (2 x 10^5 cells/well) containing 200 μL of RPMI medium. After the incubation (5 h), the supernatants were discarded and 200 μL of RPMI containing the promastigotes was added to each well at a ratio of 1:10 (cell:promastigote) and incubated (24 h). RPMI was used for removing free parasites. Then, 200 μL of different concentrations of reference drugs or GSL fraction (as described in promastigotes treatment) was added to each well and incubated (72 h). The number of 3 untreated wells were used as negative controls. Next, the supernatants were removed, and the cells were incubated with 50 mL MTT (Sigma, Lyon, France) solution (stock solution: 5 mg/mL in PBS). After the incubation, dimethyl sulfoxide (100 mL) was added to wells, rotated for 30 min and centrifuged (700 × g, 5 min). The supernatants were transferred to the new plates and scanned at 570 nm for measuring the optical absorbance using a well spectrophotometer (BioTek, Winooski, VT, USA). The cell DR was measured by the formula below:

\[
1-\left(\frac{AT}{AC}\right) \times 100
\]

where, AT means the absorbance of wells treated with different concentrations of reference drugs or GSL fraction; AC means the absorbance of negative control wells.

**Cytotoxicity and selectivity index (SI) evaluation**

The DR and SI were determined for each concentration of reference drugs or GSL fraction according to our previous study. The SI >10 represents the safety of the medication.

**Statistical analysis**

The IC_{50} and CC_{50} were analyzed by GraphPad Prism software (version v6). The IBM SPSS v20 software was used for two-tailed t-test analysis.

**RESULTS**

**Identification of the major GSLs**

The GSL fraction, obtained from anion exchange chromatography, was purified using VLC. The number of 5 fractions (A1-A5) were resulted. Based on HPLC peaks, the fraction A3 showed two peaks (Figure 1), where its major desulfo-GSL constituent was isolated by semi-preparative HPLC and identified as 3-methyl thiopropyl-GSL (glucoiberverin) (Figure 2) using NMR and EI-MS spectroscopy. ^1H-NMR: 1.90 (2H, m, CH₂-2'), 2.1 (3H, s, S-CH₃), 2.55 (2H, m, CH₂-3'), 2.66 (2H, t, J₁',₂' = 7.2, CH₂-1'), 3.2-3.4 (4H, m, H-2,3,4,5), 3.58 (1H, dd, J₅,₆ₐ = 5.2, J₆ₐ,₆₅ = 17.6, H-6a), 3.77 (1H, dd, J₅,₆₅ = 3.7, J₆₅,₆₆ = 17.6 H-6b), 4.82 (1H, d, J₁,₂ = 9.6, H-1). ^13C-NMR: 14.56 (C-4'), 26.75 (C-2'), 30.77 (C-3'), 32.97 (C-1'), 61.66 (C-6), 69.98 (C-4), 72.87 (C-2), 78.16 (C-3), 80.24 (C-5), 81.53 (C-1), 105.62 (C-5), 152 (C-7). EI-MS: The major mass fragments (m/z): 147 (R-N=C=S), 115 (R-CN), 72 (CH₂NCS⁺), 45 (CH₃S⁺).

**Total glucosinolate content**

The total GSL content was calculated as 23.28 ± 0.7 mmol equivalent of sinigrin/kg of dry sample by the following equation: y = 0.361x + 0.164, R² = 0.9916.

**Identification of the volatile compounds using GC-MS**

Based on the results, 76.91% of the total volatiles were identified as glucoiberverin hydrolysis products (Figure 3). The major compounds were recognized as 4-methyl thiobutyl nitrile (62.91%) and 3-methyl thiopropyl isothiocyanates (iberverin 14.01%), which were characterized by their retention time and MS spectra (Table 1).
Antileishmanial activity

**GSL fraction-treated promastigotes**

The highest DR for the GSL fraction was found at a concentration of 75 μg/mL (20%). The concentrations of 39 and 4.9 μg/mL of amphotericin B showed the highest (73.8%) and lowest DR (38.4%), respectively. The highest DR for glucantime was 68.2% at a concentration of 93.500 mg/mL and the lowest was 24.5% at a concentration of 700 μg/mL. A significant difference \( p < 0.05 \) was observed between the concentrations of the GSL fraction and standard drugs (amphotericin B and glucantime). The IC\(_{50}\) of amphotericin B and glucantime were calculated 8 and 95 μg/mL, respectively. This was determined 245 μg/mL for the GSL fraction (Figure 4).

**GSL fraction-treated amastigotes**

The concentrations of 625 and 75 μg/mL of GSL fraction showed the highest (59.3%) and lowest (31%) death rate, respectively. The highest DR for amphotericin B was 78% at a concentration of 39 mg/mL and the lowest was 41.8% at a concentration of 4.9 μg/mL. For glucantime, the highest and lowest death rates were 70.2% (93.500 μg/mL) and 26.8% (700 μg/mL), respectively. No significant difference was observed between different concentrations of the GSL fraction and standard drugs (amphotericin B and glucantime) \( (p > 0.05) \). IC\(_{50}\) was also 5.5 μg/mL for amphotericin B, 165 μg/mL for glucantime and 250 μg/mL for GSL fraction (Figure 5).

**Cytotoxicity test and selectivity index**

Cytotoxic concentration \( 50 \) (CC\(_{50}\)) and SI were 105 μg/mL and 19.09 for amphotericin B, 2650 μg/mL, and 16.06 for glucantime, and 3950 μg/mL and 15.8 for the GSL fraction, respectively.

**DISCUSSION**

This study reports the isolation of the main GSL constituent from *A. linifolium* seeds by ion-exchange and reversed-phase chromatography and identification of the isolated compound using EI-MS and NMR spectra for the first time. The major constituent of the GSL fraction was identified as glucoiberverin, a methyl thioglucosinolate, which was previously identified in some other *Alyssum* species such as *A. sibiricum* (as the main GSL constituents) and *A. peltarioides*. NMR and MS data of the isolated compound were confirmed with the published spectroscopic studies. A survey of the literature revealed that the methylthio and methylsulphinyl GSLs are found to be the common constituents in *Alyssum* species and the present results agree with these findings. The chemical characterization of the volatile fraction from *A."
linifolium seeds showed 4-methyl thiobutyl nitrile (iberverin nitrile, 62.91%) and 3-methyl thiopropyl isothiocyanate (iberverin, 14.01%) that are normally the hydrolysis products of glucoiberverin.  

The GSL fraction from A. linifolium seeds exhibited a considerable inhibitory effect against L. major promastigotes (45.7%) with a significant SI value of 15.8 compared to amphotericin B (19.09). Literature surveys report the anti-parasitic properties of Brassicaceae plants and their GSL constituents. Based on Montazeri et al., the hydroalcoholic extracts of some Brassicaceae plants, including Alyssum homalocarpum, provided considerable in vitro anti-toxoplasma activities. Spectrophotometric determination showed GSLs (24.37 mmol/kg dry weight) in A. homalocarpum seeds. Calzada et al. reported that the benzyl GSL isolated from Lepidium virginicum (Brassicaceae) root, possessed significant anti-amoebic activity against Entamoeba histolytica trophozoites (IC50: 100.1 μg/mL). The in vitro nematocidal activity of some GSL constituents from seeds of Brassicaceae plants was evaluated by Lazzeri et al. The hydrolysis products of GSLs such as sinigrin, glucobrassicin, and glucotropaeolin showed lethal effects on the larval stage of H. schachtii.

Infection of cells with Leishmania donovani parasites leads to an increase in anti-apoptotic Bcl-2 expression, therefore, the Bcl-2 inhibition results in eliminating of the parasites. Based on Aghaei et al., downregulation of anti-apoptotic Bcl-2 protein in macrophages infected with Leishmania parasite, promotes the apoptosis process of infected-macrophages through the changes in the mitochondrial membrane and releasing Cyt c, resulting in the parasite death. The Bcl-2 expression is also altered by aliphatic GSLs such as sulforaphane through the downregulation of anti-apoptotic Bcl-2 proteins. Therefore, this could be considered a potential mechanism of the parasite death induced by GSLs.

Different Leishmania species increase the activation of NF-kB in the host cell, resulting in the survival of the parasite and increasing the intracellular parasite burden. Therefore, NF-kB may be regarded as a target for treating leishmaniasis. It has been reported that ITCs of Brassicaceae plants can inhibit NF-kB-mediated inflammatory process and this could be considered a potential antileishmanial effect of A. linifolium.

The cell division cycle (CDC) proteins and mitogen-activated protein kinases (MAPK) play important roles in CDC and apoptosis. Based on the recent investigation, the CDC2-related kinase (CRK3) genes are involved in the life cycles (promastigote and amastigote stage) of Leishmania parasites. It appears that CRK3 is active in the G2 cell cycle of parasites and regulates the mitosis. It was reported that benzyl isothiocyanate (BITC) and phenethyl ITC decrease the cyclin-dependent kinase 1, CDC2 and CDC25C proteins and suppress G2/M phases to induce apoptosis. Therefore, the CRK3 inhibitor could be considered a novel antileishmanial drug.

The involvement of ITCs has been demonstrated in the activation of MAPK protein kinase and induction of apoptosis. Moreover, BITC induce the activation of two important MAPK signaling pathways, JNK and p38 MAPK, and promote apoptosis. Researchers observed that these two signaling pathways are involved in Leishmania disease. Moreover, several types of MAPK are involved in the life stages of Leishmania parasites. Therefore, ITCs and BITC can be considered the effective antileishmanial compounds.
Based on the present results, it seems that GSL fraction from *A. linifolium* seeds might affect the *L. major* parasites through the above pathways.

**CONCLUSION**

Based on our findings, the GSL fraction from *A. linifolium* seeds have antileishmanial activity against *L. major*. Glucoiberverin was identified as the main GSL constituent of *A. linifolium* seeds. Due to anti-parasitic activities of GSLs, these compounds could be considered promising candidates for developing new antileishmanial drugs. Consequently, it needs more investigations on the inhibitory effects of GSLs such as glucoiberverin against *L. major* in animal models and more studies should be performed to identify the molecular pathways related to the efficacy of these compounds on *Leishmania* parasite.

**Ethics**

**Ethics Committee Approval:** IR.MAZUMS.REC.1397.297 and IR.MAZUMS.REC.1398.1069.

**Informed Consent:** Not applicable.

**Peer-review:** Externally peer-reviewed.

**Authorship Contributions**

Concept: S.S., Design: S.S., M.F., Data Collection or Processing: F.M., R.F., H.K., Analysis or Interpretation: S.S., M.F., Literature Search: F.M., R.F., Writing: F.M., R.F., S.S., H.K.

**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** This work was supported by the Mazandaran University of Medical Sciences, Sari, Iran (grant number 1157 and 5922).

**REFERENCES**

1. Mozaffarian V. Dictionary of Iranian plant names. Tehran: Farhang Moaser Pub; Persian; 1996.
2. Mengoni A, Baker AJM, Bazzicalupo M, Reeves RD, Adigüzel N, Chianni E, Galardi F, Gabbricki R, Gonnelli C. Evolutionary dynamics of nickel hyperaccumulation in *Alyssum* revealed by ITS nrDNA analysis. New Phytol. 2003;159:691-699.
3. Mobi A, Mijani S, Ghanbari A, Rastgooy M. Seed germination and emergence of two flax-leaf alyssum (*Alyssum linifolium* Steph. ex. Wild.) plants in response to environmental factors. Crop Pasture Sci. 2019;70:807-813.
4. Moghanlo L, Ghahereinanjejad F, Vafadar M. Ethnobotanical study of medicinal plants in the central district of the Zanjan county, Zanjan province, Iran. J Herbal Drugs. 2019;9:121-131.
5. Prashar A, Siddiqui F, Singh AK. Synthetic and green vegetable isothiocyanates target red blood leukemia cells. Fitoterapia. 2012;83:255-265.
6. Ghasemian Lmemski E, Valadbeigi T. Evaluation of *in vitro* antimicrobial, antidiabetic and antioxidant potential of *Alyssum homolocarpum* and green synthesis of the silver nanoparticles. J Medicinal Plants By-Product. 2018;7:1-8.
7. Hamedi A, Ghanbari A, Razavipour F, Saeidi V, Zarshenas MM, Sohrabpour M, Azari H. *Alyssum homolocarpum* seeds: phytochemical analysis and effects of the seed oil on neural stem cell proliferation and differentiation. J Nat Med. 2015;69:387-396.
8. Montazeri M, Mirzaei F, Daryani A, Naeimayi R, Moradi Karimabad S, Khalilzadeh Arjmandi H, Esmaelzadeh N, Shahani S. Anti-toxoplasma activities of the hydroalcoholic extract of some Brassicaceae species. Adv Biomed Res. 2020;9:5.
9. Jahangir M, Kim HK, Choi YH, Verpoorte R. Health-affecting compounds in Brassicaceae. Compr Rev Food Sci. 2009;8:31-43.
10. Sotelo T, Lema M, Soengas P, Cartea M, Velasco P. *In vitro* activity of glucosinolates and their degradation products against *Brassica*-pathogenic bacteria and fungi. Appl Environ Microbiol. 2015;81:432-440.
11. Vig AP, Rampal G, Thind TS, Arora S. Bio-protective effects of glucosinolates - a review. LWT-Food Sci Technol. 2009;42:1561-1572.
12. Lazzeri L, Tacconi R, Palmieri S. *In vitro* activity of some glucosinolates and their reaction products toward a population of the nematode *Heterodera schachtii*. J Agric Food Chem. 1993;41:825-829.
13. Calzada F, Barbosa E, Cedillo-Rivera R. Antiamoebic activity of benzyl glucosinolate from *Lepidium virginicum*. Phytother Res. 2003;17:618-619.
14. Torres-Guerrero E, Quintanilla-Cedillo MR, Ruiz-Esmenjaud J, Arenas R. Leishmaniasis: a review. F1000Res. 2017;6:750.
15. Costa CH, Werncke GL, Costa DL, Holanda TA, Aguiar GB, Carvalho AS, Cavalcanti JC, Santos LS. Is severe visceral leishmaniasis a systemic inflammatory response syndrome? A case control study. Rev Soc Bras Med Trop. 2010;43:386-392.
16. de Menezes JP, Guedes CE, Petersen AL, Fragia DB, Veras PS. Advances in development of new treatment for leishmaniasis. Biomed Res Int. 2015;2015:815023.
17. Mirzaee F, Mohammadi H, Azarpeik S, Amiri FT, Shahani S. Attenuation of liver mitochondrial oxidative damage by the extract and desulfo glucosinolate fraction of *Lepidium perfoliatum* L. seeds. S Afr J Bot. 2021;138:377-385.
18. Blažević I, De Nicola GR, Montaut S, Rollin P, Ruščić M. Glucosinolate profile of croatian stenoendemic plant *Fibizia triquetra* (DC.) Boiss. ex Prantić. Croat Chem Acta. 2015;88:307-314.
19. Jezek J, Haggett BG, Atkinson A, Rawson DM. Determination of glucosinolates using their alkaline degradation and reaction with ferricyanide. J Agric Food Chem. 1999;47:4669-4674.
20. Žekić M, Radonić A, Marijanović Z. Glucosinolate profiling of *Calepina irregularis*. Nat Prod Commun. 2016;11:1329-1332.
21. Ashoori F, Fakhar M, Goli RG. Glucosinolate composition of seeds from 297 species of wild plants. J. New Sect. Nat Prod. 2021;14:20201-20206.
22. Wallsgrove RM. High-performance liquid chromatographic separation of natural and synthetic desulphoglucosinolates and their chemical
validation by UV, NMR and chemical ionisation-MS methods. Phytochem Anal. 2001;12:226-242.

26. Prestera T, Fahey JW, Holtzclaw WD, Abeygunawardana C, Kachinski JL, Talalay P. Comprehensive chromatographic and spectroscopic methods for the separation and identification of intact glucosinolates. Anal Biochem. 1996;239:168-179.

27. Hasapis X, MacLeod AJ, Moreau M. Glucosinolates of nine Cruciferae and two Capparaceae species. Phytochemistry. 1981;20:2355-2358.

28. Fahey JW, Zalcmann AT, Talalay P. The chemical diversity and distribution of glucosinolates and isothiocyanates among plants. Phytochemistry. 2001;56:5-51.

29. Vaughn SF, Berhow MA. Glucosinolate hydrolysis products from various plant sources: pH effects, isolation, and purification. Ind Crops Prod. 2005;21:193-202.

30. Steverding D, Michaels S, Read KD. In vitro and in vivo studies of trypanocidal activity of dietary isothiocyanates. Planta Med. 2014;80:183-186.

31. Younus I, Siddiq A. In vitro antileishmanial activity of Raphanus sativus L. var. caudatus. J Basic Appl Sci. 2016;12:242-244.

32. Verma NK, Singh G, Dey CS. Mitofosine induces apoptosis in arsenite-resistant Leishmania donovani promastigotes through mitochondrial dysfunction. Exp Parasitol. 2007;116:1-13.

33. Tang L, Zhang Y. Mitochondria are the primary target in isothiocyanate-induced apoptosis in human bladder cancer cells. Mol Cancer Ther. 2005;4:1250-1259.

34. Pandey RK, Mehrotra S, Sharma S, Gudde RS, Sundar S, Shaha C. Leishmania donovani-induced increase in macrophage Bcl-2 favors parasite survival. Front Immunol. 2016;7:456.

35. Aghaei M, KhanAhmad H, Aghaei S, Ali Nilforoushzadeh M, Mohaghegh MA, Hejazi SH. The role of bax in the apoptosis of Leishmania-infected macrophages. Microb Pathog. 2019;139:103892.

36. Choi WY, Choi BT, Lee WH, Choi YH. Sulforaphane generates reactive oxygen species leading to mitochondrial perturbation for apoptosis in human leukemia U937 cells. Biomed Pharmacother. 2008;62:637-644.

37. Guizani-Tabbane L, Ben-Aissa K, Belgith M, Sassi A, Dellagi K. Leishmania major amastigotes induce p50/c-Rel NF-xB transcription factor in human macrophages: involvement in cytokine synthesis. Infect Immun. 2004;72:2582-2589.

38. Navarro SL, Li F, Lampe JW. Mechanisms of action of isothiocyanates in cancer chemoprevention: an update. Food Funct. 2011;2:579-587.

39. Molina-Vargas LA. Mechanism of action of isothiocyanates. A review. Agron Colomb. 2013;31:68-75.

40. Grant KM, Dunion MH, Yardley V, Skaltsounis AL, Marko D, Eisenbrand G, Croft SL, Meijer L, Mottram JC. Inhibitors of Leishmania mexicana CRK3 cyclin-dependent kinase: chemical library screen and antileishmanial activity. Antimicrob Agents Chemother. 2004;48:3033-3042.

41. Xiao D, Vogel V, Singh SV. Benzyl isothiocyanate-induced apoptosis in human breast cancer cells is initiated by reactive oxygen species and regulated by Bax and Bak. Mol Cancer Ther. 2006;5:2931-2945.

42. Junghae M, Raynes JG. Activation of p38 mitogen-activated protein kinase attenuates Leishmania donovani infection in macrophages. Infect Immun. 2002;70:5026-5035.

43. Keighobadi M, Akhtari J, Fakhar M, Emami S, Mirzaei H. An overview on anticancer drugs with antileishmanial activity. J Mazandaran Univ Med Sci. 2018;28:154-165.